Annual Changes to the Nasdaq-100 Index(R)

(NASDAQ:NDAQ), NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index(R) (NDX(R)), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Ferrovial SE […]

OWL ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Blue Owl Capital Inc. Investors

(NYSE:OWL), NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Blue Owl Capital (“Blue Owl” or the “Company”) (NYSE:OWL) securities during the period of February 6, 2025 through November 16, 2025, inclusive (“the Class

EWTN Honors Doug Keck with 2025 Mother Angelica Award

EWTN Global Catholic Network is pleased to announce that veteran broadcaster and longtime media executive DougKeck received the 2025 Mother Angelica Award – the Network's highest honor – in recognition of his decades of service, faithful leadership, and tireless commitment to the mission of evangelization. https://mma.prnewswire.com/media/2844070/doug_keck_mother_angelica_award.jpg Following his retirement from administrative duties as EWTN President

Milestone Receives FDA Approval of CARDAMYST(TM) (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Receives FDA Approval of CARDAMYST(TM) (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) GlobeNewswire December 13, 2025 First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA

Goodwood Inc. Announces Reopening of the Goodwood Capital Fund

Goodwood Inc. Announces Reopening of the Goodwood Capital Fund GlobeNewswire December 13, 2025 TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Goodwood Inc. (“Goodwood“), the manager of Goodwood Capital Fund (the “Fund“), announced today, following notice to unitholders of the Fund on December 5, 2025, that the Fund will not proceed with its previously approved termination

Annual Changes to the Nasdaq-100 Index(R)

Annual Changes to the Nasdaq-100 Index(R) GlobeNewswire December 13, 2025 NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index(R) (NDX(R)), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to

AI Infrastructure Company EverMind Released EverMemOS, Responding to Profound Challenges in AI

AI infrastructure companyEverMind has recently released EverMemOS, an open-source Memory Operating System designed to address one of artificial intelligence's most profound challenges: equipping machines with scalable, long-term memory. The Memory Bottleneck For years, large language models (LLMs) have been constrained by fixed context windows, a limitation that causes “forgetfulness” in long-term tasks. This results in

Global Times: Eternal memory on our land ï¼In mourning for the victims of the Nanjing Massacre

On December 13, 1937, Japanese aggressors brutally occupiedNanjing in East China's Jiangsu Province and carried out the horrific Nanjing Massacre, resulting in the slaughter of over 300,000 Chinese people. This atrocity stands as a monstrous crime against humanity and an exceedingly dark chapter in human history. This year marks the 80th anniversary of the victory

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia–(Newsfile Corp. – December 12, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the “2022 Warrants”)

Scroll to Top